Understanding the pathophysiology of Pseudomonas aeruginosa colonization as a guide for future treatment for chronic leg ulcers

Abstract

Chronic leg wounds represent a major burden of disease worldwide, costing health care systems billions of dollars each year. Aside from the financial implications, they also impose a significant physical and psychosocial burden on the patient, their relatives and/or carers, and the community. Whilst measures such as maintenance of wound hygiene, debridement, dressings and compression are the current standard of care, complete healing is not always achievable and ulcer recurrence is common. Thus, there is still a gap to breach in terms of understanding the intricate pathophysiology of chronic wounds and the role this plays on treatment and management. Pseudomonas aeruginosa has been linked to poor wound healing, with the pathogen being frequently isolated from chronic leg ulcers. Characterized by its multi-drug resistance, targeting P. aeruginosa requires the development of novel therapeutic options. Thus, the aim of this literature review is to describe the pathophysiology of P. aeruginosa in chronic leg ulcers and discuss novel treatment strategies. Here, we describe the key molecular mechanisms driving the observed clinical effect of P. aeruginosa on wounds and discuss novel strategies of molecular targeting of this common bacteria, establishing new approaches that could benefit patients with chronic hard to heal wounds.

Keywords

Pseudomonas aeruginosa / Treatment / Chronic wound / Future treatment / Leg ulcers

References

[1] Serra R, Grande R, Butrico L, Rossi A, Settimio UF, Caroleo B, et al. Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus. Expert Rev Anti-Infect Ther. 2015; 13: 605- 13. https://doi.org/10.1586/14787210.2015.1023291.

[2] Wolcott RD, Rhoads DD. A study of biofilm-based wound management in subjects with critical limb ischaemia. J Wound Care. 2008; 17: 145-8, 150-2-4-5. https://doi.org/10.12968/jowc.2008.17.4.28835.

[3] Alhussain FA, Yenugadhati N, Al Eidan FA, Al Johani S, Badri M. Risk factors, antimicrobial susceptibility pattern and patient outcomes of Pseudomonas aeruginosa infection: a matched case-control study. J Infect Public Health. 2021; 14: 152-7. https://doi.org/10.1016/j.jiph.2020.11.010.

[4] Gjodsbol K, Christensen JJ, Karlsmark T, Jorgensen B, Klein BM, Krogfelt KA. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J. 2006; 3: 225-31. https://doi.org/10.1111/j.1742-481X.2006.00159.x.

[5] Toale C, Kelly A, Leahy F, Meagher H, Stapleton PJ, Moloney MA, et al. Effect of Pseudomonas colonisation on lower limb venous ulcer healing: a systematic review. J Wound Care. 2022; 31: 186-92. https://doi.org/10.12968/jowc.2022.31.2.186.

[6] Davies CE, Wilson MJ, Hill KE, Stephens P, Hill CM, Harding KG, et al. Use of molecular techniques to study microbial diversity in the skin: chronic wounds reevaluated. Wound Repair Regen. 2001; 9: 332-40. https://doi.org/10.1046/j.1524-475x.2001.00332.x.

[7] Murali TS, Kavitha S, Spoorthi J, Bhat DV, Prasad ASB, Upton Z, et al. Characteristics of microbial drug resistance and its correlates in chronic diabetic foot ulcer infections. J Med Microbiol. 2014; 63: 1377-85. https://doi.org/10.1099/jmm.0.076034-0.

[8] Moore K, Hall V, Paull A, Morris T, Brown S, McCulloch D, et al. Surface bacteriology of venous leg ulcers and healing outcome. J Clin Pathol. 2010; 63: 830-4. https://doi.org/10.1136/jcp.2010.077032.

[9] Morton LM, Phillips TJ. Wound healing and treating wounds: differential diagnosis and evaluation of chronic wounds. J Am Acad Dermatol. 2016; 74: 589-605-quiz 605-6.

[10] Ruffin M, Brochiero E. Repair process impairment by Pseudomonas aeruginosa in epithelial tissues: major features and potential therapeutic avenues. Front Cell Infect Microbiol. 2019; 9: 182. https://doi.org/10.3389/fcimb.2019.00182.

[11] Schwarzer C, Fischer H, Machen TE. Chemotaxis and binding of Pseudomonas aeruginosa to scratch-wounded human cystic fibrosis airway epithelial cells. PLoS One. 2016; 11: e0150109. https://doi.org/10.1371/journal.pone.0150109.

[12] Kazmierczak BI, Schniederberend M, Jain R. Cross-regulation of Pseudomonas motility systems: the intimate relationship between flagella, pili and virulence. Curr Opin Microbiol. 2015; 28: 78-82. https://doi.org/10.1016/j.mib.2015.07.017.

[13] Chang Y, Wang PC, Ma HM, Chen SY, Fu YH, Liu YY, et al. Design, synthesis and evaluation of halogenated furanone derivatives as quorum sensing inhibitors in Pseudomonas aeruginosa. Eur J Pharm Sci. 2019; 140: 105058. https://doi.org/10.1016/j.ejps.2019.105058.

[14] Shao X, Xie Y, Zhang Y, Liu J, Ding Y, Wu M, et al. Novel therapeutic strategies for treating Pseudomonas aeruginosa infection. Expert Opin Drug Discov. 2020; 15: 1403-23. https://doi.org/10.1080/17460441.2020.1803274.

[15] Garcia M, Morello E, Garnier J, Barrault C, Garnier M, Burucoa C, et al. Pseudomonas aeruginosa flagellum is critical for invasion, cutaneous persistence and induction of inflammatory response of skin epidermis. Virulence. 2018; 9: 1163-75. https://doi.org/10.1080/21505594.2018.1480830.

[16] Pier GB.Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol. 2007; 297: 277-95. https://doi.org/10.1016/j.ijmm.2007.03.012.

[17] Rocchetta HL, Burrows LL, Lam JS. Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 1999; 63: 523-53. https://doi.org/10.1128/MMBR.63.3.523-553.1999.

[18] Doughty MJ, Laiquzzaman M, Muller A, Oblak E, Button NF. Central corneal thickness in European (white) individuals, especially children and the elderly, and assessment of its possible importance in clinical measures of intra-ocular pressure. Ophthalmic Physiol Opt. 2002; 22: 491-504. https://doi.org/10.1046/j.1475-1313.2002.00053.x.

[19] Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Wiener-Kronish JP, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med. 1999; 5: 392-8. https://doi.org/10.1038/7391.

[20] Morihara K, Tsuzuki H, Oka T, Inoue H, Ebata M, Pseudomonas aeruginosa Elastase. Isolation, crystallization, and preliminary characterization. J Biol Chem. 1965; 240: 3295-304. https://doi.org/10.1016/S0021-9258(18)97217-0.

[21] Okuda K, Morihara K, Atsumi Y, Takeuchi H, Kawamoto S, Kawasaki H, et al. Complete nucleotide sequence of the structural gene for alkaline proteinase from Pseudomonas aeruginosa IFO 3455. Infect Immun. 1990; 58: 4083-8. https://doi.org/10.1128/iai.58.12.4083-4088.1990.

[22] Wysocki AB, Bhalla-Regev SK, Tierno PM, Jr, Stevens-Riley M, Wiygul RC.Proteolytic activity by multiple bacterial species isolated from chronic venous leg ulcers degrades matrix substrates. Biol Res Nurs. 2013; 15: 407-15. https://doi.org/10.1177/1099800412464683.

[23] Galle M, Carpentier I, Beyaert R. Structure and function of the type III secretion system of Pseudomonas aeruginosa. Curr Protein Pept Sci. 2012; 13: 831-42. https://doi.org/10.2174/138920312804871210.

[24] Bonemann G, Pietrosiuk A, Mogk A. Tubules and donuts: a type VI secretion story. Mol Microbiol. 2010; 76: 815-21. https://doi.org/10.1111/j.1365-2958.2010.07171.x.

[25] Balasubramanian D, Schneper L, Kumari H, Mathee K. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res. 2013; 41: 1-20. https://doi.org/10.1093/nar/gks1039.

[26] Rahim K, Saleha S, Zhu X, Huo L, Basit A, Franco OL. Bacterial contribution in chronicity of wounds. Microb Ecol. 2017; 73: 710-21. https://doi.org/10.1007/s00248-016-0867-9.

[27] James GA, Swogger E, Wolcott R, Pulcini E, Secor P, Sestrich J, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008; 16: 37-44. https://doi.org/10.1111/j.1524-475X.2007.00321.x.

[28] Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002; 295: 1487. https://doi.org/10.1126/science.295.5559.1487.

[29] Nithya C, Begum MF, Pandian SK. Marine bacterial isolates inhibit biofilm formation and disrupt mature biofilms of Pseudomonas aeruginosa PAO1. Appl Microbiol Biotechnol. 2010; 88: 341-58. https://doi.org/10.1007/s00253-010-2777-y.

[30] Harmsen M, Yang L, Pamp SJ, Tolker-Nielsen T. An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal. FEMS Immunol Med Microbiol. 2010; 59: 253-68. https://doi.org/10.1111/j.1574-695X.2010.00690.x.

[31] Stacey SD, Williams DA, Pritchett CL. The Pseudomonas aeruginosa two-component regulator AlgR directly activates rsmA expression in a phosphorylation-independent manner. J Bacteriol. 2017; 199. https://doi.org/10.1128/JB.00048-17.

[32] Huang H, Shao X, Xie Y, Wang T, Zhang Y, Wang X, et al. An integrated genomic regulatory network of virulence-related transcriptional factors in Pseudomonas aeruginosa. Nat Commun. 2019; 10: 2931.

[33] Mulcahy LR, Isabella VM, Lewis K. Pseudomonas aeruginosa biofilms in disease. Microb Ecol. 2014; 68: 1-12. https://doi.org/10.1007/s00248-013-0297-x.

[34] Wagner VE, Li LL, Isabella VM, Iglewski BH. Analysis of the hierarchy of quorum-sensing regulation in Pseudomonas aeruginosa. Anal Bioanal Chem. 2007; 387: 469-79. https://doi.org/10.1007/s00216-006-0964-6.

[35] Pier GB, Coleman F, Grout M, Franklin M, Ohman DE. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect Immun. 2001; 69: 1895-901. https://doi.org/10.1128/IAI.69.3.1895-1901.2001.

[36] Moskowitz SM, Ernst RK. The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection. Subcell Biochem. 2010; 53: 241-53. https://doi.org/10.1007/978-90-481-9078-2_11.

[37] Jacobsen JN, Andersen AS, Sonnested MK, Laursen I, Jorgensen B, Krogfelt KA. Investigating the humoral immune response in chronic venous leg ulcer patients colonised with Pseudomonas aeruginosa. Int Wound J. 2011; 8: 33-43. https://doi.org/10.1111/j.1742-481X.2010.00741.x.

[38] Fazli M, Bjarnsholt T, Kirketerp-Moller K, Jorgensen A, Andersen CB, Givskov M, et al. Quantitative analysis of the cellular inflammatory response against biofilm bacteria in chronic wounds. Wound Repair Regen. 2011; 19: 387-91. https://doi.org/10.1111/j.1524-475X.2011.00681.x.

[39] Travis J, Potempa J, Maeda H. Are bacterial proteinases pathogenic factors? Trends Microbiol. 1995; 3: 405-7. https://doi.org/10.1016/S0966-842X(00)88988-X.

[40] Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996; 60: 539-74. https://doi.org/10.1128/mr.60.3.539-574.1996.

[41] Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J Immunol. 2005; 175: 7512-8. https://doi.org/10.4049/jimmunol.175.11.7512.

[42] Burmolle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homoe P, et al. Biofilms in chronic infections-a matter of opportunity-monospecies biofilms in multispecies infections. FEMS Immunol Med Microbiol. 2010; 59: 324-36. https://doi.org/10.1111/j.1574-695X.2010.00714.x.

[43] Uberoi A, McCready-Vangi A, Grice EA. The wound microbiota: microbial mechanisms of impaired wound healing and infection. Nat Rev Microbiol. 2024; 22: 507-21. https://doi.org/10.1038/s41579-024-01035-z.

[44] Buhl M, Peter S, Willmann M. Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: a systematic review. Expert Rev Anti-Infect Ther. 2015; 13: 1159-70. https://doi.org/10.1586/14787210.2015.1064310.

[45] Turner KH, Everett J, Trivedi U, Rumbaugh KP, Whiteley M. Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection. PLoS Genet. 2014; 10: e1004518. https://doi.org/10.1371/journal.pgen.1004518.

[46] Omar A, Wright JB, Schultz G, Burrell R, Nadworny P. Microbial Biofilms and Chronic Wounds Microorganisms. 2017; 5: 1.

[47] Eriksson E, Liu PY, Schultz GS, Martins-Green MM, Tanaka R, Weir D, et al. Chronic wounds: treatment consensus. Wound Repair Regen. 2022; 30: 156-71. https://doi.org/10.1111/wrr.12994.

[48] Falcone M, De Angelis B, Pea F, Scalise A, Stefani S, Tasinato R, et al. Challenges in the management of chronic wound infections. J Glob Antimicrob Resist. 2021; 26: 140-7. https://doi.org/10.1016/j.jgar.2021.05.010.

[49] Moscati RM, Mayrose J, Reardon RF, Janicke DM, Jehle DV. A multicenter comparison of tap water versus sterile saline for wound irrigation. Acad Emerg Med. 2007; 14: 404-9. https://doi.org/10.1197/j.aem.2007.01.007.

[50] Cwajda-Bialasik J, Moscicka P, Szewczyk MT. Antiseptics and antimicrobials for the treatment and management of chronic wounds: a systematic review of clinical trials. Postepy Dermatol Alergol. 2022; 39: 141-51. https://doi.org/10.5114/ada.2022.113807.

[51] Horrocks A. Prontosan wound irrigation and gel: management of chronic wounds. Br J Nurs. 2006; 15: 1222-4. https://doi.org/10.12968/bjon.2006.15.22.22559.

[52] Madhusudhan VL. Efficacy of 1% acetic acid in the treatment of chronic wounds infected with Pseudomonas aeruginosa: prospective randomised controlled clinical trial. Int Wound J. 2016; 13: 1129-36. https://doi.org/10.1111/iwj.12428.

[53] Powers JG, Higham C, Broussard K, Phillips TJ. Wound healing and treating wounds: chronic wound care and management. J Am Acad Dermatol. 2016; 74: 607-25-quiz 625-6.

[54] Leaper D. Appropriate use of silver dressings in wounds: international consensus document. Int Wound J. 2012; 9: 461-4. https://doi.org/10.1111/j.1742-481X.2012.01091.x.

[55] Guan H, Dong W, Lu Y, Jiang M, Zhang D, Aobuliaximu Y, et al. Distribution and antibiotic resistance patterns of pathogenic bacteria in patients with chronic cutaneous wounds in China. Front Med (Lausanne). 2021; 8: 609584. https://doi.org/10.3389/fmed.2021.609584.

[56] Taylor PK, Yeung AT, Hancock RE. Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies. J Biotechnol. 2014; 191: 121-30. https://doi.org/10.1016/j.jbiotec.2014.09.003.

[57] Tchakal-Mesbahi A, Metref M, Singh VK, Almpani M, Rahme LG. Characterization of antibiotic resistance profiles in Pseudomonas aeruginosa isolates from burn patients. Burns. 2021; 47: 1833-43. https://doi.org/10.1016/j.burns.2021.03.005.

[58] Rashid Mahmood A, Mansour HN. Study of antibiotic resistant genes in Pseudomonas aeroginosa isolated from Burns and wounds. Arch Razi Inst. 2022; 77: 403-11. https://doi.org/10.22092/ARI.2021.356681.1893.

[59] Abbas M, Uckay I, Lipsky BA. In diabetic foot infections antibiotics are to treat infection, not to heal wounds.Expert Opin Pharmacother. 2015; 16: 821-32. https://doi.org/10.1517/14656566.2015.1021780.

[60] Finlayson KJ, Parker CN, Miller C, Gibb M, Kapp S, Ogrin R, et al. Predicting the likelihood of venous leg ulcer recurrence: the diagnostic accuracy of a newly developed risk assessment tool. Int Wound J. 2018; 15: 686-94. https://doi.org/10.1111/iwj.12911.

[61] Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents. 2015; 45: 568-85. https://doi.org/10.1016/j.ijantimicag.2015.03.001.

[62] Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 2003; 22: 3803-15. https://doi.org/10.1093/emboj/cdg366.

[63] Kumar L, Chhibber S, Kumar R, Kumar M, Harjai K. Zingerone silences quorum sensing and attenuates virulence of Pseudomonas aeruginosa. Fitoterapia. 2015; 102: 84-95. https://doi.org/10.1016/j.fitote.2015.02.002.

[64] Park S, Kim HS, Ok K, Kim Y, Park HD, Byun Y. Design, synthesis and biological evaluation of 4-(alkyloxy)-6-methyl-2H-pyran-2-one derivatives as quorum sensing inhibitors. Bioorg Med Chem Lett. 2015; 25: 2913-7. https://doi.org/10.1016/j.bmcl.2015.05.054.

[65] Gera S, Kankuri E, Kogermann K. Antimicrobial peptides-unleashing their therapeutic potential using nanotechnology. Pharmacol Ther. 2022; 232: 107990. https://doi.org/10.1016/j.pharmthera.2021.107990.

[66] Dijksteel GS, Ulrich MMW, Middelkoop E, Boekema B. Review: lessons learned from clinical trials using antimicrobial peptides (AMPs). Front Microbiol. 2021; 12: 616979. https://doi.org/10.3389/fmicb.2021.616979.

[67] Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother. 2014; 58: 4384-91. https://doi.org/10.1128/AAC.02643-14.

[68] Que YA, Lazar H, Wolff M, Francois B, Laterre PF, Mercier E, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014; 33: 1861-7. https://doi.org/10.1007/s10096-014-2156-1.

[69] Nilsson E, Larsson A, Olesen HV, Wejaker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol. 2008; 43: 892-9. https://doi.org/10.1002/ppul.20875.

[70] Yang F, Gu J, Yang L, Gao C, Jing H, Wang Y, et al. Protective efficacy of the trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in murine pneumonia and burn models. Sci Rep. 2017; 7: 3957.

[71] Kim DK, Kim JJ, Kim JH, Woo YM, Kim S, Yoon DW, et al. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine. 2000; 19: 1274-83. https://doi.org/10.1016/S0264-410X(00)00235-8.

[72] Sainz-Mejias M, Jurado-Martin I, McClean S. Understanding Pseudomonas aeruginosa-host interactions: the ongoing quest for an efficacious vaccine. Cells. 2020; 9: 2617. https://doi.org/10.3390/cells9122617.

[73] Hart RJ, Morici LA. Vaccination to prevent Pseudomonas aeruginosa bloodstream infections. Front Microbiol. 2022; 13: 870104. https://doi.org/10.3389/fmicb.2022.870104.

[74] Divithotawela C, Pham A, Ledger EL, Hopkins P, Wells TJ, Chambers D. Treatment of life-threatening Pseudomonas aeruginosa infection by pheresis of inhibitory antibodies. J Heart Lung Transplant. 2020; 39: 87-9. https://doi.org/10.1016/j.healun.2019.10.001.

[75] Wells TJ, Davison J, Sheehan E, Kanagasundaram S, Spickett G, MacLennan CA, et al. The use of plasmapheresis in patients with bronchiectasis with Pseudomonas aeruginosa infection and inhibitory antibodies. Am J Respir Crit Care Med. 2017; 195: 955-8. https://doi.org/10.1164/rccm.201603-0599LE.

[76] Smith RS, Iglewski BH. P. aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol 2003; 6: 56-60, DOI: https://doi.org/10.1016/S1369-5274(03)00008-0.

[77] Wagner S, Sommer R, Hinsberger S, Lu C, Hartmann RW, Empting M, et al. Novel strategies for the treatment of Pseudomonas aeruginosa infections. J Med Chem. 2016; 59: 5929-69. https://doi.org/10.1021/acs.jmedchem.5b01698.

[78] Muhlen S, Dersch P. Anti-virulence strategies to target bacterial infections. Curr Top Microbiol Immunol. 2016; 398: 147-83. https://doi.org/10.1007/82_2015_490.

[79] Hodgkinson JT, Galloway WR, Wright M, Mati IK, Nicholson RL, Welch M, et al. Design, synthesis and biological evaluation of non-natural modulators of quorum sensing in Pseudomonas aeruginosa. Org Biomol Chem. 2012; 10: 6032-44. https://doi.org/10.1039/c2ob25198a.

[80] Amara N, Mashiach R, Amar D, Krief P, Spieser SA, Bottomley MJ, et al. Covalent inhibition of bacterial quorum sensing. J Am Chem Soc. 2009; 131: 10610-9. https://doi.org/10.1021/ja903292v.

[81] Kumar L, Chhibber S, Harjai K. Zingerone inhibit biofilm formation and improve antibiofilm efficacy of ciprofloxacin against Pseudomonas aeruginosa PAO1. Fitoterapia. 2013; 90: 73-8. https://doi.org/10.1016/j.fitote.2013.06.017.

[82] Yeung AT, Gellatly SL, Hancock RE. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci. 2011; 68: 2161-76. https://doi.org/10.1007/s00018-011-0710-x.

[83] Myhrman E, Hakansson J, Lindgren K, Bjorn C, Sjostrand V, Mahlapuu M. The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections. Appl Microbiol Biotechnol. 2013; 97: 3085-96. https://doi.org/10.1007/s00253-012-4439-8.

[84] Bjorn C, Noppa L, Naslund Salomonsson E, Johansson AL, Nilsson E, Mahlapuu M, et al. Efficacy and safety profile of the novel antimicrobial peptide PXL150 in a mouse model of infected burn wounds. Int J Antimicrob Agents. 2015; 45: 519-24. https://doi.org/10.1016/j.ijantimicag.2014.12.015.

[85] Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol. 2011; 239: 27-34. https://doi.org/10.1007/s00232-011-9343-0.

[86] Ganz T.Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3: 710-20. https://doi.org/10.1038/nri1180.

[87] Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol. 2012; 32: 143-71.

[88] Lehrer RI, Lu W. Alpha-defensins in human innate immunity. Immunol Rev. 2012; 245: 84-112. https://doi.org/10.1111/j.1600-065X.2011.01082.x.

[89] Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol. 2007; 127: 594-604. https://doi.org/10.1038/sj.jid.5700599.

[90] Kosciuczuk EM, Lisowski P, Jarczak J, Strzalkowska N, Jozwik A, Horbanczuk J, et al. Cathelicidins: family of antimicrobial peptides.A review Mol Biol Rep. 2012; 39: 10957-70. https://doi.org/10.1007/s11033-012-1997-x.

[91] Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006; 1758: 1408-25. https://doi.org/10.1016/j.bbamem.2006.03.030.

[92] Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology. 2002; 106: 20-6. https://doi.org/10.1046/j.1365-2567.2002.01398.x.

[93] Ramos R, Silva JP, Rodrigues AC, Costa R, Guardao L, Schmitt F, et al. Wound healing activity of the human antimicrobial peptide LL37. Peptides. 2011; 32: 1469-76. https://doi.org/10.1016/j.peptides.2011.06.005.

[94] Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003; 120: 379-89. https://doi.org/10.1046/j.1523-1747.2003.12069.x.

[95] Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007; 60: 1206-15. https://doi.org/10.1093/jac/dkm357.

[96] Shatri G. Tadi P. StatPearls: Polymyxin, 2023.

[97] Gorr SU, Flory CM, Schumacher RJ. In vivo activity and low toxicity of the second-generation antimicrobial peptide DGL13K. PLoS One. 2019; 14:e0216669. https://doi.org/10.1371/journal.pone.0216669.

[98] Chung EMC, Dean SN, Propst CN, Bishop BM, van Hoek ML. Komodo dragon-inspired synthetic peptide DRGN-1 promotes wound-healing of a mixed-biofilm infected wound. NPJ Biofilms Microbiomes. 2017; 3: 9. https://doi.org/10.1038/s41522-017-0017-2.

[99] Zhong G, Cheng J, Liang ZC, Xu L, Lou W, Bao C, et al. Short synthetic beta-sheet antimicrobial peptides for the treatment of multidrug-resistant Pseudomonas aeruginosa burn wound infections. Adv Healthc Mater. 2017; 6. https://doi.org/10.1002/adhm.201601134.

[100] Steinstraesser L, Tack BF, Waring AJ, Hong T, Boo LM, Fan MH, et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother. 2002; 46: 1837-44. https://doi.org/10.1128/AAC.46.6.1837-1844.2002.

[101] Liu Y, Li S, Shen T, Chen L, Zhou J, Shi S, et al. N-terminal Myristoylation enhanced the antimicrobial activity of antimicrobial peptide PMAP-36PW. Front Cell Infect Microbiol. 2020; 10: 450. https://doi.org/10.3389/fcimb.2020.00450.

[102] Kang HK, Seo CH, Luchian T, Park Y. Pse-T2, an antimicrobial peptide with high-level, broad-Spectrum antimicrobial potency and skin biocompatibility against multidrug-resistant Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2018; 62. https://doi.org/10.1128/AAC.01493-18.

[103] Chalekson CP, Neumeister MW, Jaynes J. Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel). Plast Reconstr Surg. 2002; 109: 1338-43. https://doi.org/10.1097/00006534-200204010-00020.

[104] Grassi L, Batoni G, Ostyn L, Rigole P, Van den Bossche S, Rinaldi AC, et al. The antimicrobial peptide lin-SB056-1 and its Dendrimeric derivative prevent Pseudomonas aeruginosa biofilm formation in physiologically relevant models of chronic infections. Front Microbiol. 2019; 10: 198. https://doi.org/10.3389/fmicb.2019.00198.

[105] Sader HS, Dale GE, Rhomberg PR, Flamm RK. Antimicrobial activity of Murepavadin tested against clinical isolates of Pseudomonas aeruginosa from the United States, Europe, and China. Antimicrob Agents Chemother. 2018; 62. https://doi.org/10.1128/AAC.00311-18.

[106] Bessa LJ, Manickchand JR, Eaton P, Leite J, Brand GD, Gameiro P. Intragenic antimicrobial peptide Hs02 hampers the proliferation of single-and dual-species biofilms of P. aeruginosa and S. Aureus: a promising agent for mitigation of biofilm-associated infections. Int J Mol Sci. 2019; 20. https://doi.org/10.3390/ijms20143604.

[107] Melvin JA, Lashua LP, Kiedrowski MR, Yang G, Deslouches B, Montelaro RC, et al. Simultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus-Bacterium Coinfection mSphere. 2016; 1. https://doi.org/10.1128/mSphere.00083-16.

[108] Bayramov D, Li Z, Patel E, Izadjoo M, Kim H, Neff J. A novel peptide-based antimicrobial wound treatment is effective against biofilms of multi-drug resistant wound pathogens. Mil Med. 2018; 183: 481-6. https://doi.org/10.1093/milmed/usx135.

[109] (U.S). NLoM.Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers. Identifier NCT01594762.

[110] Brown KL, Poon GF, Birkenhead D, Pena OM, Falsafi R, Dahlgren C, et al. Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J Immunol. 2011; 186: 5497-505. https://doi.org/10.4049/jimmunol.1002508.

[111] Wei Y, Wu J, Chen Y, Fan K, Yu X, Li X, et al. Efficacy and safety of PL-5 (Peceleganan) spray for wound infections: a phase IIb randomized clinical trial. Ann Surg. 2023; 277: 43-9. https://doi.org/10.1097/SLA.0000000000005508.

[112] Mensa B, Howell GL, Scott R, DeGrado WF. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014; 58: 5136-45. https://doi.org/10.1128/AAC.02955-14.

[113] Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 2014; 149: 528-36. https://doi.org/10.1001/jamasurg.2013.4841.

[114] Lundgren S, Wallblom K, Fisher J, Erdmann S, Schmidtchen A, Saleh K. Study protocol for a phase 1, randomised, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of ascending topical doses of TCP-25 applied to epidermal suction blister wounds in healthy male and female volunteers. BMJ Open. 2023; 13: e064866. https://doi.org/10.1136/bmjopen-2022-064866.

[115] Magana M, Pushpanathan M, Santos AL, Leanse L, Fernandez M, Ioannidis A, et al. The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis. 2020; 20: e216-30. https://doi.org/10.1016/S1473-3099(20)30327-3.

[116] Pal I, Bhattacharyya D, Kar RK, Zarena D, Bhunia A, Atreya HS. A peptide-nanoparticle system with improved efficacy against multidrug resistant bacteria. Sci Rep. 2019; 9: 4485. https://doi.org/10.1038/s41598-019-41005-7.

[117] Comune M, Rai A, Chereddy KK, Pinto S, Aday S, Ferreira AF, et al. Antimicrobial peptide-gold nanoscale therapeutic formulation with high skin regenerative potential. J Control Release. 2017; 262: 58-71. https://doi.org/10.1016/j.jconrel.2017.07.007.

[118] Severino P, Silveira EF, Loureiro K, Chaud MV, Antonini D, Lancellotti M, et al. Antimicrobial activity of polymyxin-loaded solid lipid nanoparticles (PLX-SLN): characterization of physicochemical properties and in vitro efficacy. Eur J Pharm Sci. 2017; 106: 177-84. https://doi.org/10.1016/j.ejps.2017.05.063.

[119] Zhu C, Zhao J, Kempe K, Wilson P, Wang J, Velkov T, et al. A hydrogel-based localized release of colistin for antimicrobial treatment of burn wound infection. Macromol Biosci. 2017; 17. https://doi.org/10.1002/mabi.201600320.

[120] Gatti JW, Smithgall MC, Paranjape SM, Rolfes RJ, Paranjape M. Using electrospun poly(ethylene-oxide) nanofibers for improved retention and efficacy of bacteriolytic antibiotics. Biomed Microdevices. 2013; 15: 887-93. https://doi.org/10.1007/s10544-013-9777-5.

[121] Song DW, Kim SH, Kim HH, Lee KH, Ki CS, Park YH. Multi-biofunction of antimicrobial peptide-immobilized silk fibroin nanofiber membrane: implications for wound healing. Acta Biomater. 2016; 39: 146-55. https://doi.org/10.1016/j.actbio.2016.05.008.

[122] Anantharajah A, Mingeot-Leclercq MP, Van Bambeke F. Targeting the type three secretion system in Pseudomonas aeruginosa. Trends Pharmacol Sci. 2016; 37: 734-49. https://doi.org/10.1016/j.tips.2016.05.011.

[123] Brutinel ED, Vakulskas CA, Brady KM, Yahr TL. Characterization of ExsA and of ExsA-dependent promoters required for expression of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol. 2008; 68: 657-71. https://doi.org/10.1111/j.1365-2958.2008.06179.x.

[124] Grier MC, Garrity-Ryan LK, Bartlett VJ, Klausner KA, Donovan PJ, Dudley C, et al. N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability. Bioorg Med Chem Lett. 2010; 20: 3380-3. https://doi.org/10.1016/j.bmcl.2010.04.014.

[125] Song Y, Yang C, Chen G, Zhang Y, Seng Z, Cai Z, et al. Molecular insights into the master regulator CysB-mediated bacterial virulence in Pseudomonas aeruginosa. Mol Microbiol. 2019; 111: 1195-210. https://doi.org/10.1111/mmi.14200.

[126] Rahme LG, Ausubel FM, Cao H, Drenkard E, Goumnerov BC, Lau GW, et al. Plants and animals share functionally common bacterial virulence factors. Proc Natl Acad Sci USA. 2000; 97: 8815-21. https://doi.org/10.1073/pnas.97.16.8815.

[127] Waligora EA, Ramsey DM, Pryor EE, Jr, Lu H, Hollis T, Sloan GP, et al. AmrZ beta-sheet residues are essential for DNA binding and transcriptional control of Pseudomonas aeruginosa virulence genes. J Bacteriol. 2010; 192: 5390-401. https://doi.org/10.1128/JB.00711-10.

[128] Hendrickson EL, Plotnikova J, Mahajan-Miklos S, Rahme LG, Ausubel FM. Differential roles of the Pseudomonas aeruginosa PA14 rpoN gene in pathogenicity in plants, nematodes, insects, and mice. J Bacteriol. 2001; 183: 7126-34. https://doi.org/10.1128/JB.183.24.7126-7134.2001.

[129] Romero M, Silistre H, Lovelock L, Wright VJ, Chan KG, Hong KW, et al. Genome-wide mapping of the RNA targets of the Pseudomonas aeruginosa riboregulatory protein RsmN. Nucleic Acids Res. 2018; 46: 6823-40. https://doi.org/10.1093/nar/gky324.

[130] Shao X, Zhang X, Zhang Y, Zhu M, Yang P, Yuan J, et al. RpoN-dependent direct regulation of quorum sensing and the type VI secretion system in Pseudomonas aeruginosa PAO1. J Bacteriol. 2018; 200. https://doi.org/10.1128/JB.00205-18.

[131] Liang H, Deng X, Ji Q, Sun F, Shen T, He C. The Pseudomonas aeruginosa global regulator VqsR directly inhibits QscR to control quorum-sensing and virulence gene expression. J Bacteriol. 2012; 194: 3098-108. https://doi.org/10.1128/JB.06679-11.

[132] Liang H, Deng X, Li X, Ye Y, Wu M. Molecular mechanisms of master regulator VqsM mediating quorum-sensing and antibiotic resistance in Pseudomonas aeruginosa. Nucleic Acids Res. 2014; 42: 10307-20. https://doi.org/10.1093/nar/gku586.

[133] Kong W, Zhao J, Kang H, Zhu M, Zhou T, Deng X, et al. ChIP-seq reveals the global regulator AlgR mediating cyclic di-GMP synthesis in Pseudomonas aeruginosa. Nucleic Acids Res. 2015; 43: 8268-82. https://doi.org/10.1093/nar/gkv747.

[134] Zhao J, Yu X, Zhu M, Kang H, Ma J, Wu M, et al. Structural and molecular mechanism of CdpR involved in quorum-sensing and bacterial virulence in Pseudomonas aeruginosa. PLoS Biol. 2016; 14: e1002449. https://doi.org/10.1371/journal.pbio.1002449.

[135] Zhang Y, Zhou CM, Pu Q, Wu Q, Tan S, Shao X, et al. Pseudomonas aeruginosa regulatory protein AnvM controls pathogenicity in anaerobic environments and impacts host Defense. MBio. 2019; 10. https://doi.org/10.1128/mBio.01362-19.

[136] Maisuria VB, Los Santos YL, Tufenkji N, Deziel E. Cranberry-derived proanthocyanidins impair virulence and inhibit quorum sensing of Pseudomonas aeruginosa. Sci Rep. 2016; 6: 30169. https://doi.org/10.1038/srep30169.

[137] Merakou C, Schaefers MM, Priebe GP. Progress toward the elusive Pseudomonas aeruginosa vaccine. Surg Infect. 2018; 19: 757-68. https://doi.org/10.1089/sur.2018.233.

[138] Korpi F, Hashemi FB, Irajian G, Fatemi MJ, Laghaei P, Behrouz B. Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model. Immunol Lett. 2016; 176: 8-17. https://doi.org/10.1016/j.imlet.2016.04.002.

[139] Lazar H, Horn MP, Zuercher AW, Imboden MA, Durrer P, Seiberling M, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother. 2009; 53: 3442-6. https://doi.org/10.1128/AAC.01699-08.

[140] Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27: 1. https://doi.org/10.1186/s12929-019-0592-z.

[141] Sousa SA, Seixas AMM, Marques JMM, Leitao JH. Immunization and immunotherapy approaches against Pseudomonas aeruginosa and Burkholderia cepacia complex infections. Vaccines (Basel). 2021; 9. https://doi.org/10.3390/vaccines9060670.

[142] Jain R, Beckett VV, Konstan MW, Accurso FJ, Burns JL, Mayer-Hamblett N, et al. KB001-a, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018; 17: 484-91. https://doi.org/10.1016/j.jcf.2017.12.006.

[143] Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and therapeutic use of IgM antibodies. Antibodies (Basel) 2020; 9: 53. https://doi.org/10.3390/antib9040053.

[144] Cazander G, Jukema GN, Nibbering PH. Complement activation and inhibition in wound healing. Clin Dev Immunol. 2012; 2012: 534291. https://doi.org/10.1155/2012/534291.

[145] Janeway CA, Jr.How the immune system protects the host from infection. Microbes Infect. 2001; 3: 1167-71. https://doi.org/10.1016/S1286-4579(01)01477-0.

[146] Waisbren BA, Brown I. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. J Immunol. 1966; 97: 431-7. https://doi.org/10.4049/jimmunol.97.3.431.

[147] Holby N, Olling S. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases. Acta Pathol Microbiol Scand C. 1977; 85: 107-14.

[148] MacLennan CA, Gilchrist JJ, Gordon MA, Cunningham AF, Cobbold M, Goodall M, et al. Dysregulated humoral immunity to nontyphoidal salmonella in HIV-infected African adults. Science. 2010; 328: 508-12. https://doi.org/10.1126/science.1180346.

[149] Coggon CF, Jiang A, Goh KGK, Henderson IR, Schembri MA, Wells TJ. A novel method of serum resistance by Escherichia coli that causes urosepsis. MBio. 2018; 9. https://doi.org/10.1128/mBio.00920-18.

[150] Wells TJ, Whitters D, Sevastsyanovich YR, Heath JN, Pravin J, Goodall M, et al. Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing. J Exp Med. 2014; 211: 1893-904. https://doi.org/10.1084/jem.20132444.

[151] Pham A, Ledger EL, Coggon CF, Henderson IR, Reid DW, Bell SC, et al. Anti-LPS IgA and IgG can inhibit serum killing of Pseudomonas aeruginosa in patients with cystic fibrosis. Infect Immun. 2021; 89:e0041221. https://doi.org/10.1128/IAI.00412-21.

[152] Mikucionyte GD, Dambrauskiene A, Skrodeniene E, Vitkauskiene A. Biofilm formation and serum susceptibility in Pseudomonas aeruginosa. Open Medicine. 2014; 9: 187-92. https://doi.org/10.2478/s11536-013-0241-y.

[153] Young LS, Armstrong D, Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972; 126: 257-76. https://doi.org/10.1093/infdis/126.3.257.

[154] Divithotawela C, Pham A, Bell PT, Ledger EL, Tan M, Yerkovich S, et al. Inferior outcomes in lung transplant recipients with serum Pseudomonas aeruginosa specific cloaking antibodies. J Heart Lung Transplant. 2021; 40: 951-9. https://doi.org/10.1016/j.healun.2021.05.016.

[155] Hickson SM, Hoehensteiger JK, Mayer-Coverdale J, Torres VVL, Feng W, Monteith JN, et al. Antibody-mediated serum resistance protects Pseudomonas aeruginosa during bloodstream infections. J Infect Dis. 2024. https://doi.org/10.1093/infdis/jiad457.

[156] Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019; 25: 219-32. https://doi.org/10.1016/j.chom.2019.01.014.

[157] Mohan N, Bosco K, Peter A, Abhitha K, Bhat SG. Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review. Arch Microbiol. 2024; 206: 443. https://doi.org/10.1007/s00203-024-04168-0.

[158] Norton P, Trus P, Wang F, Thornton MJ, Chang CY. Understanding and treating diabetic foot ulcers: insights into the role of cutaneous microbiota and innovative therapies.Skin Health Dis. 2024; 4: e399. https://doi.org/10.1002/ski2.399.

[159] Pinto AM, Cerqueira MA, Bañobre-Lópes M, Pastrana LM, Sillankorva S. Bacteriophages for chronic wound treatment: from traditional to novel delivery systems.Viruses. 2020; 12. https://doi.org/10.3390/v12020235.

[160] Alipour-Khezri E, Skurnik M, Zarrini G. Pseudomonas aeruginosa bacteriophages and their clinical applications. Viruses. 2024; 16: 1051. https://doi.org/10.3390/v16071051.

[161] Mohamed WF, Askora AA, Mahdy MMH, El-Hussieny EA, Abu-Shady HM. Isolation and characterization of bacteriophages active against Pseudomonas aeruginosa strains isolated from diabetic foot infections. Arch Razi Inst. 2022; 77: 2187-200. https://doi.org/10.22092/ARI.2022.359032.2357.

[162] Kifelew LG, Warner MS, Morales S, Gordon DL, Thomas N, Mitchell JG, et al. Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers. Sci Rep. 2024; 14: 3515. https://doi.org/10.1038/s41598-024-53317-4.

[163] Tagliaferri TL, Rhode S, Muñoz P, Simon K, Krüttgen A, Stoppe C, et al. Antiseptic management of critical wounds: differential bacterial response upon exposure to antiseptics and first insights into antiseptic/phage interactions. Int J Surg. 2024; 110: 5374-84. https://doi.org/10.1097/JS9.0000000000001605.

[164] Akturk E, Melo LDR, Oliveira H, Crabbé A, Coenye T, Azeredo J. Combining phages and antibiotic to enhance antibiofilm efficacy against an in vitro dual species wound biofilm. Biofilms. 2023; 6: 100147. https://doi.org/10.1016/j.bioflm.2023.100147.

[165] Abo, Kamer AM, Abdelaziz AA, Nosair AM, Al-Madboly LA. Characterization of newly isolated bacteriophage to control multi-drug resistant Pseudomonas aeruginosa colonizing incision wounds in a rat model: in vitro and in vivo approach. Life Sci. 2022; 310: 121085. https://doi.org/10.1016/j.lfs.2022.121085.

[166] Euler CW, Raz A, Hernandez A, Serrano A, Xu S, Andersson M, et al. PlyKp104, a novel phage lysin for the treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and other gram-negative ESKAPE pathogens. Antimicrob Agents Chemother. 2023; 67: e0151922. https://doi.org/10.1128/aac.01519-22.

[167] Gupta P, Singh HS, Shukla VK, Nath G, Bhartiya SK. Bacteriophage therapy of chronic nonhealing wound: clinical study. Int J Low Extrem Wounds. 2019; 18: 171-5. https://doi.org/10.1177/1534734619835115.

[168] Patel DR, Bhartiya SK, Kumar R, Shukla VK, Nath G. Use of customized bacteriophages in the treatment of chronic nonhealing wounds: a prospective study. Int J Low Extrem Wounds. 2021; 20: 37-46. https://doi.org/10.1177/1534734619881076.

[169] Metsemakers WJ, Onsea J, Moriarty TF, Pruidze N, Nadareishvili L, Dadiani M, et al. Bacteriophage therapy for human musculoskeletal and skin/soft tissue infections. Clin Microbiol Infect. 2023; 29: 695-701. https://doi.org/10.1016/j.cmi.2023.01.011.

[170] Merabishvili M, Pirnay JP, De Vos D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol Biol. 2024; 2734: 49-66.

[171] Sillankorva S, Pires L, Pastrana LM, Bañobre-López M. Antibiofilm efficacy of the Pseudomonas aeruginosa Pbunavirus vB_PaeM-SMS29 loaded onto dissolving polyvinyl alcohol microneedles. Viruses. 2022; 14. https://doi.org/10.3390/v14050964.

[172] Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022; 22: e208-20. https://doi.org/10.1016/S1473-3099(21)00612-5.